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Abstract
Background: To prospectively evaluate the efficacy and safety of selective internal radiation (SIR)
spheres in patients with inoperable liver metastases from colorectal cancer who have failed 5FU
based chemotherapy.
Methods:  Patients were prospectively enrolled at three Australian centres. All patients had
previously received 5-FU based chemotherapy for metastatic colorectal cancer. Patients were
ECOG 0–2 and had liver dominant or liver only disease. Concurrent 5-FU was given at investigator
discretion.
Results: Thirty patients were treated between January 2002 and March 2004. As of July 2004 the
median follow-up is 18.3 months. Median patient age was 61.7 years (range 36 – 77). Twenty-nine
patients are evaluable for toxicity and response. There were 10 partial responses (33%), with the
median duration of response being 8.3 months (range 2–18) and median time to progression of 5.3
mths. Response rates were lower (21%) and progression free survival shorter (3.9 mths) in patients
that had received all standard chemotherapy options (n = 14). No responses were seen in patients
with a poor performance status (n = 3) or extrahepatic disease (n = 6). Overall treatment related
toxicity was acceptable, however significant late toxicity included 4 cases of gastric ulceration.
Conclusion: In patients with metastatic colorectal cancer that have previously received treatment
with 5-FU based chemotherapy, treatment with SIR-spheres has demonstrated encouraging
activity. Further studies are required to better define the subsets of patients most likely to respond.
Background
Colorectal cancer (CRC) is the most common GI malig-
nancy accounting for 4718 deaths in Australia [1] and
almost 437,000 deaths worldwide annually making it the
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most third most common malignancy in the developed
world [2]. Around fifty to sixty percent of these patients
will develop liver metastases, and in approximately 20%
of cases the liver is the only site of disease at death[3]. Sur-
gical resection of all apparent disease is possible in
selected patients, however for the majority of patients
with metastatic CRC the standard approach remains sys-
temic chemotherapy.
Selective Internal Radiation (SIR) spheres (Sirtex Medical,
Sydney, Australia) are a new radiotherapeutic treatment
for liver metastases. These resin microspheres contain
yttrium, a high energy beta-emitting isotope, and are
embolised into the hepatic artery where they become
lodged within the microvasculature of the tumour. The
treatment is relatively selective as hepatic tumours derive
their blood supply almost exclusively from the hepatic
artery whereas normal liver parenchyma is supplied pre-
dominantly by the portal circulation. Animal studies sug-
gest that SIR spheres allow on average 200–300 Gy to be
delivered to liver tumours [4]. In contrast the delivery of
standard external beam radiation therapy to the whole
liver is limited by the ability of the normal parenchyma to
tolerate only 30–35 Gy, an insufficient dose to produce a
significant anti-tumour effect [5].
Encouraging results have been reported following previ-
ous studies of SIR spheres in metastatic colorectal cancer.
In a series of 21 chemonaive patients with colorectal liver
metastases who were randomised to receive intravenous
5FU alone or intravenous 5FU plus SIR spheres, the com-
bination demonstrated a higher response rate and signifi-
cantly improved progression free survival compared to
chemotherapy alone [6]. In a larger study of 74 patients
combining SIR-spheres with hepatic artery chemotherapy
superior response rates and time to progression over treat-
ment with chemotherapy alone were seen in patients with
colorectal cancer [7]. With the exception of hepatocellular
carcinoma[8] results in other tumour types have not been
so encouraging [9].
We report here the first prospective series conducted to
better define the efficacy and safety of SIR-
spheres(Yttrium90) in patients with colorectal cancer and
liver metastases that have previously received 5-FU based
chemotherapy. No financial support was received from
SIRTex for the purposes of this study.
Methods
Data for consecutive patients with metastatic colorectal
cancer treated with Sirtex microspheres were collected
prospectively across 3 Australian centres from Jan 2002
and March 2004. During this period of the time both
oxaliplatin and irinotecan were not reimbursable in Aus-
tralia as part of first-line therapy for patients with meta-
static colorectal cancer outside of a clinical trial. These
agents were available for patients that had progressed fol-
lowing initial 5-FU based treatment.
Patients were informed of the available evidence regard-
ing SIR-spheres treatment. Patients that elected to proceed
with treatment were informed that data would be col-
lected prospectively as part of a research project. Toxicities
and protocols were outlined in accordance with the man-
ufacturer's guidelines and were common across all partic-
ipating centres. Patients were considered eligible if they
had liver metastases from colorectal cancer with histolog-
ical confirmation of their primary tumour. All patients
were required to have measurable disease within the liver.
Extra-hepatic disease was allowed if the liver was the dom-
inant site of disease.
Patients with an expected survival of less than 3 months,
documented brain metastases, or a poor performance sta-
tus (ECOG >2) were excluded. Adequate hepatic, renal
and liver function was required including a normal clot-
ting profile, an albumin >30 g/L, bilirubin <20 umol/L
and no evidence of liver decompensation such as ascites
or portal hypertension was permitted. Patients with portal
vein thrombosis were also excluded from this study.
Previous treatment with chemotherapy was allowed pro-
vided this had been more than 2 months prior to planned
treatment with SIR-spheres. Patients received bolus 5FU
chemotherapy concurrent with the SIR-spheres, as a radi-
osensitiser, and subsequently in responding patients at
the investigator's discretion.
Pre treatment workup and disease evaluation
All patients underwent a standard pre-treatment evalua-
tion as per manufacturers guidelines. An hepatic angi-
ogram was performed to define arterial anatomy prior to
treatment and to permit a nuclear medicine scan with
radio labeled Tc 99 m-MAA (macro-aggregated albumin)
in order to exclude patients at high risk of lung (radiation
pneumonitis) or GI toxicity (gastric/duodenal ulceration)
due to hepato-systemic shunting or aberrant vasculature.
The fraction of extra-hepatic shunting was determined for
each patient as a percentage. Patients who had shunting of
greater than 20% were excluded from the study. Shunting
of between 12 and 20% resulted in a reduction in the dos-
age of spheres delivered. The final dose of SIR-spheres
administered in units of GBq was calculated according to
each patient's body surface area and percentage of tumour
involvement of liver (an assessment made by the radiolo-
gist after viewing the baseline CT scan). Across the three
participating centres, the workup and delivery of SIR
spheres was performed by a total of four experienced
interventional radiologists with two centres having allBMC Cancer 2005, 5:132 http://www.biomedcentral.com/1471-2407/5/132
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treatment administered by a single interventional
radiologist.
Following a single treatment of SIR-spheres, two weeks
after the MAA scan, patients were routinely followed and
assessed at monthly intervals. Acute toxicity was assessed
initially and at subsequent clinical visits. All toxicities
were graded according to National Cancer Institute (NCI)
Common Toxicity Criteria, and performance status
according to Eastern Cooperative Oncology Group
(ECOG) criteria. Disease evaluation was performed by CT
imaging at 2 months and bi-monthly thereafter until dis-
ease progression. A complete response (CR) was defined
as the disappearance of all target lesions. A partial
response (PR) was defined as >30 percent decrease in the
sum of the longest dimension of the target lesions at 2
months. All responses were confirmed on repeat imaging.
Progressive disease (PD) was defined as a >20 percent
increase in the sum of the longest recorded target lesion(s)
within the liver or the development of new or progressive
extrahepatic disease. Stable disease (SD) was defined as a
decrease not sufficient to qualify for a PR nor an increase
not sufficient to qualify for PD. The results of all staging
investigations and toxicity assessments were collected and
analysed prospectively. The duration of response was
determined from the date of the first response evaluation
at 2 months until progressive disease.
Results
Patient characteristics
A total of 30 patients underwent treatment between Janu-
ary 2002 and March 2004.(see table 1). There were 22
males and 8 females with a median age of 61.7 years
(range 36–77). Ninety percent of patients had an ECOG
performance status of 0 or 1. Twenty percent of patients
(6) had low-volume extra-hepatic disease, the remainder
of the patients had liver-only disease. All patients had
failed 5FU chemotherapy and 22 (73%) patients had
failed either oxaliplatin or irinotecan containing regi-
mens, with 14 (46%) having progressed through both. 21
of the 30 patients received 5-FU concurrent with the SIR-
spheres.
Of the 30 patients treated, 29 are evaluable for disease
response. One patient presented shortly after treatment
with worsening liver function tests, liver failure and death
considered by the investigator to likely be from rapid dis-
ease progression. This was not confirmed with imaging.
Overall, there were 10 partial responses (33% of all 30
patients treated). Of note ongoing responses were seen in
a number of patients, with continued reduction in the size
of liver lesions occurring out to 12 months from treat-
ment. One patient with an initial partial response had
achieved a complete response at six months. The median
duration of response is 8.3 months (range between 2–18+
months) at a median follow up time (as of July 2004) of
18.3 months for all patients. Eight patients in total had
stable disease at 2 months (27%) and the remaining 12
(40%) had disease progression (n = 11) or were not eval-
uable (n = 1). The median time to progression for all
patients was 5.3 mths, however, patients who achieved a
partial response within the liver as a group had a median
progression free survival of 9.2 mths. See table 2
All responses occurred in patients with disease confined to
the liver (n = 24) and no responses were seen in patients
with a performance status of 2 (n = 3). In the 8 patients
that had received only prior 5-FU there were 6 responses
(75%). In the patients that had received oxaliplatin and/
or irinotecan (n = 22) there were 5 responses (23%). This
included responses in 3 of 14 (21%) patients that had pre-
viously received all standard chemotherapy options. No
other factors were apparently predictive of response,
including the bulk of disease, in this study.
Toxicity
Overall toxicity assessments were carried out according to
NCI common toxicity criteria at all three centres. The find-
ings were consistent across all study sites with between 2–
8 weeks of lethargy, anorexia, nausea and RUQ pain being
observed to a variable extent in most patients. However,
in most cases, these side effects were mild and self-limit-
ing following treatment with standard anti-emetics and
analgesics medication. Three patients reported severe nau-
sea and lethargy for 2 weeks following treatment and
moderate symptoms were reported in several patients up
to 1 month following treatment.
Serious treatment related toxicities clearly related to treat-
ment with SIR-spheres were recorded in 4 patients (13%)
who had gastric/duodenal ulceration confirmed on gas-
troscopy. In 3 of these patients, SIR-spheres were seen in
biopsies taken from ulcerated mucosa (Figure 3) and in
two patients there was rapid improvement following
treatment with proton pump inhibitors. However, one
patient had severe ongoing and disabling pain, anorexia
Table 1: Patient Characteristics
Total Number 30
Male 22 (73%)
Female 8 (27%)
ECOG 0 16 (53%)
ECOG 1 11 (37%)
ECOG 2 3 (10%)
Extra-hepatic disease 7 (20%)
Failed 5FU alone 8 (27%)
Failed 5FU + CPT-11 and Oxaliplatin 14 (46%)
Failed 5FU + either CPT-11 or Oxaliplatin 8 (27%)BMC Cancer 2005, 5:132 http://www.biomedcentral.com/1471-2407/5/132
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and nausea that continued until the time of death 3
months later and another patient experienced ongoing
symptoms beyond 3 months, despite the use of proton
pump inhibitors.
Other serious toxicity potentially related to SIR-spheres
included a single patient who was admitted to hospital
with acute right upper quadrant pain and marked deterio-
ration in her liver function tests one month following
treatment with SIR-spheres. The clinical assessment was
that the patient likely had radiation hepatitis. Her symp-
toms settled with conservative management.
Discussion
This prospective evaluation documents the experience in
our three institutions of using Selective Internal Radiation
spheres to treat liver metastases from colorectal cancer in
patients that had previously received 5-FU chemotherapy.
Our series adds to the published experience documenting
the activity of this treatment in selected patients, along
with the potential for significant toxicity. For the period of
this study oxaliplatin and irinotecan were available in
Australia only for patients that had progressed following
initial 5-FU based treatment and this is reflected in the
study design.
Overall in our experience, treatment with SIR-spheres
demonstrated promising activity in pre-treated patients
with liver metastases from colorectal cancer. Partial
responses were seen in six of the eight patients that had
failed 5FU alone. This includes one patient that was able
to undergo potentially curative resection of residual liver
disease after further response to systemic chemotherapy
and she remains disease free 22 months later. The
response rate in our series is similar to that reported in the
previous small randomized study where this combination
was used first-line [7]. The progression free and overall
survival data for our study are shown in Figure 3. Due to
the small patients numbers this activity may partly reflect
chance or patient selection. However, this is encouraging
efficacy as the alternative treatment for these patients
would have been irinotecan alone or oxaliplatin plus 5-
FU where responses are typically seen in less than 20% of
patients [10,11].
Significant response rates were also seen in patients that
had progressed through several lines of chemotherapy.
Notably, fourteen of these patients had previously
received both irinotecan and oxaliplatin, and the response
rate was maintained in this group. The only treatment
other option open to these patients would be cetuximab,
a monoclonal antibody directed at the epidermal growth
factor receptor (EGFR). As a single agent responses are
seen in about 10% of patients [12] and response rates are
higher when concurrent irinotecan is administered [12].
However, not all patients are suitable for cetuximab as
approximately 25% of patients do not express the
EGFR[13]. Based on our results SIR-spheres appear to be a
good option for patients with colorectal cancer who have
liver only disease and maintain a good performance status
following progression on all standard chemotherapy
Table 2: Results At 2 months by patient group (*1 patient died prior to the first evaluation and has been classified as progressive 
disease).
Partial Response (%) Stable Disease (%) Progressive Disease (%)
Overall (n = 30) 10 (33%) 8 (27%) 12 (40%)*
Failed 5FU alone (n = 8) 6 1 1*
Failed 5FU and CPT-11 and Oxal (n = 14) containing regimens 3 2 8
Failed 5FU and either CPT-11 or Oxaliplatin (n = 8) containing regimens 2 2 4
Extra-Hepatic disease (n = 7) 0 2 5
ECOG 2 (n = 3) 0 1 2
Biopsy of gastric mucosa showing inflammation (gastritis)  from several SIR spheres, clearly visible Figure 3
Biopsy of gastric mucosa showing inflammation (gastritis) 
from several SIR spheres, clearly visible.BMC Cancer 2005, 5:132 http://www.biomedcentral.com/1471-2407/5/132
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drugs. The suggestion from our results is that benefit from
the addition of SIR-spheres will be greater if used earlier,
but this will need to be confirmed in larger studies.
The toxicity data from our experience was consistent with
findings from earlier trials involving SIR-spheres. The
13% severe gastric/duodenal ulceration rate is significant
and is consistent with a recent larger study reporting a
12% GI ulceration rate [14]. Gastrointestinal ulceration
occurred despite strictly adhered to protocols of pre-treat-
ment workup and treatment only by experienced inter-
ventional radiologists. The product information
recommends routine use of a H-2 antagonist prophylacti-
cally the day before the procedure and for a month after-
wards in view of the known association of peptic
ulceration with SIR-spheres treatment [15]. Although this
was not part of our treatment protocol, the prophylactic
use of proton-pump inhibitors or H-2 antagonists should
be considered in patients treated with SIR-spheres. In our
analysis there were no apparent indicators of which
patients were likely to experience toxicity. In particular
this did not appear related to disease bulk or patient per-
formance status.
Conclusion
In summary, this series has demonstrated that treatment
with SIR-spheres produces encouraging responses in pre-
treated patients with colorectal cancer. Further studies in
this group of patients should be pursued. On the basis of
our results, thought should be given to stratifying patients
according to the presence or absence of extrahepatic dis-
ease and according to performance status. We have also
demonstrated the potential for significant toxicity, and
such treatment should only be conducted in centres with
experienced interventional radiologists.
The results of ongoing phase I/II trials that are exploring
the combination of SIR-spheres with multi-agent chemo-
therapy (including irinotecan and oxaliplatin containing
regimens) are eagerly awaited. Ultimately however, there
remains a need for large phase III clinical trials evaluating
the efficacy of standard therapy plus SIR-spheres com-
pared to standard therapy alone. Such trials will define the
true value of SIR-spheres and will permit insight into opti-
mal patient selection. Finally the financial costs of this
Survival curves for the 30 patients treated Figure 1
Survival curves for the 30 patients treated.
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new treatment are not insignificant and future studies will
also need to clearly demonstrate cost effectiveness as well
as efficacy in an environment where the costs of treating
patients with colorectal cancer are rapidly escalating [16].
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